期刊文献+

对比帕洛诺司琼与昂丹司琼用于头颈癌化疗止吐中的临床效果 被引量:2

下载PDF
导出
摘要 目的比较帕洛诺司琼与昂丹司琼用于头颈癌化疗止吐中的临床效果。方法选取我院收治的128例头颈癌化疗患者作为研究对象,使用随机数字表分为A、B两组,每组64例,两组患者均按照相同的化疗方案进行化疗,A组患者应用帕洛诺司琼止吐,B组应用昂丹司琼止吐,对比两组患者的止吐效果。结果 A组患者急性呕吐期和延迟呕吐期的止吐总有效率均显著高于B组,差异均具有统计学意义(P<0.05)。结论对头颈癌化疗患者应用帕洛诺司琼,比应用昂丹司琼的止吐效果更好,且安全性好,是一种安全、有效的化疗止吐方案。
作者 饶关武
出处 《湖北科技学院学报(医学版)》 2017年第3期212-213,共2页 Journal of Hubei University of Science and Technology(Medical Sciences)
  • 相关文献

参考文献2

二级参考文献15

  • 1陈艳,丁莉坤,孟玲燕,丁黎,杨林,文爱东.盐酸帕洛诺司琼注射液人体药动学研究[J].中国新药杂志,2007,16(10):806-809. 被引量:14
  • 2Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron [ J ]. Ann Oncol, 2003,14 (10) : 1570 - 1577.
  • 3Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology[ J]. Ther Clin Risk Manag, 2007,3 (6) : 1009 - 1020.
  • 4Siddiqui MA, Scott LJ. Palonosetron [ J ]. Drugs, 2004,64 (10) :1125 - 1132.
  • 5Stohz R, Cyong JC, Shaha, et al. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist,in U. S. and Japanese healthy subjects[J]. J Clin Pharmacol, 2004,44(5 ) :520 -531.
  • 6Eisenberg P, Mackintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study[J]. Ann Oncol, 2004,15(2) :330-337.
  • 7Hunt TL, Gallagher SC, Cullen MT, et al. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects [ J ]. J Clin Pharmacol, 2005,45 (5) :589 -596.
  • 8Aapro MS, Grunberg SM, Manikhas GM, et al. A phase Ⅲ, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy [ J ]. Ann Oncol, 2006,17(9) :1441-1449.
  • 9Piraccini G,Stolz R,Tei M,et al.Pharmacokinetic features of a novel 5-HT3-receptor antagonist:palonosetron (RS 25259-197)[J].Proc Am Soc Clin Oncol 2001(20):400a (Abstr 1595).
  • 10Macciocchi A,Gallagher S.A phase II dose-ranging study to assess single intravenous doses of palonosetron for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting[J].Proc Am Soc Clin Oncol,2002(21):471a (Abstr 1480).

共引文献52

同被引文献19

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部